Back

Impact of atorvastatin on serum oestradiol and estrone concentrations in postmenopausal women with chronic coronary artery disease: a randomized trial.

30 August 2025 (12:15 - 13:00)
Organised by: Logo
Congress Presentation Part of: Cardiovascular disease in women around the world Cardiovascular Disease in Women ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Miss Nathalia Faria

Heart Institute (InCor) HCFMUSP, Sao Paulo (Brazil)

7 More presentations in this session

Presentation thumbnail
Sex differences in health status trajectories among Chinese patients with angina pectoris: insights from the GREAT registry study
Professor X. Du (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Sex disparities in ischaemic heart disease mortality in South Asia: a global burden of disease 2021 analysis
Ms T. Rahaman (Bologna, IT)
Abstract Slides Video
Presentation thumbnail
Coronary artery disease-related sudden cardiac arrest in women
Doctor O. Weizman (Paris, FR)
Abstract Slides Video
Presentation thumbnail
Empagliflozin significantly reduces circulating markers of endothelial dysfunction in Ischemia with Non-Obstructive Coronary Arteries (INOCA) and coronary microvascular dysfunction: a pilot trial
Doctor O. Quesada (Cincinnati, US)
Abstract Slides Video
Presentation thumbnail
Bridging the gender gap in TAVI: real-world evidence from a single-centre study
Doctor R. Batista Louro (Evora, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiovascular disease in women around the world

The Event

Event poster

ESC Congress 2025

30 August 2025 12:15 CET
You may be interested in
thumbnail
Congress Presentation
Follow-up after acute coronary syndrome: advancing cardiovascular risk management
thumbnail
Congress Presentation
Effect of statin therapy on long-term mortality among patients with myocardial infarction with non-obstructive coronary arteries (MINOCA)
thumbnail
Congress Presentation
Sex-specific effects of apixaban versus aspirin in subclinical atrial fibrillation: insights from the ARTESiA trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources